
Agriculture
December 27, 2023
AquaFilter Family
Read SolutionImplemented by
Aquabox, UK
Updated on February 15, 2024
·Created on September 6, 2017
Q-POC is a portable rapid PCR testing device including SARS COV 2
Q-POC is a solar-powered or wind-up handheld tool designed to diagnose, manage, monitor, and track infections and drug resistance. DNA-based diagnostics can be performed at point-of-care in 10-20 minutes with Q-POC. The device also includes GPS-enabled epidemiological surveillance. Q-POC is currently in a prototype stage and is expected to be commercialized soon. Single use test cartridges are being developed for Warfarin dosage, malaria and drug resistance, hospital acquired infections, and tumor profiling.)
Target SDGs
SDG 3: Good Health and Well-Being
Market Suggested Retail Price
$1,000.00
Target Users (Target Impact Group)
Small and Medium-sized Enterprises, Public Sector Agencies, NGOs
Distributors / Implementing Organizations
Currently unknown, but QuantuMDx is partnered with several NGOs, including FIND, the Bill and Melinda Gates Foundation, the Clinton Foundation, and the Global Good Fund.
Regions
Africa, Asia
Manufacturing/Building Method
QuantuMDx has partnered with Integrated Technologies Ltd. to manufacture batches of prototypes and eventually mass produce the final product.
Intellectural Property Type
Patent
User Provision Model
Unknown, as the product has not been commercialized yet.
Distributions to Date Status
N/A, product commercialization expected 2019
Consumables
Testing cassettes
Detection sensitivity
99%, 10 to 50 copies/mL
Sensitivity : No ‘indeterminate’ result
Indispensable equipment for function (Y/N)
Yes, testing cassettes
Maintenance or calibration required by user at time of use? (Y/N)
No
Number of Tests Performed
The Q-POC can currently generate diagnostics for SARs COV 2
Power supply type: Continuous, Recharging only (V, time required, battery life), Other
Continuous power supply from Mains with 100-240V, 50-60Hz
and Li-Ion 14.4V / 6.90Ah / 99.40Wh Battery
Time required for procedure (minutes)
approximately 30 minutes
Design Specifications
The Q-POC is a portable, battery-operated diagnostics device that can process blood, urine, sputum, tissue, and swabs and delivers results in 10-20 minutes.
Results are displayed on a touchscreen and can be stored on the device, sent to a printer, or transferred to a computer or the Cloud via USB or WiFi.
Globally distributed Q-POC devices will also geotag and anonymize pathogen data and send to the cloud for real-time disease and drug resistance monitoring.
[caption id="attachment_63588" align="alignnone" width="400"] Technical Specifications of Q-POC[/caption]
Technical Support
Provided by the manufacturer
Replacement Components
Testing cassettes
Lifecycle
Unknown
Manufacturer Specified Performance Parameters
QuantuMDx seeks Q-POC can provide personalized medicine, be portable, provide a quick diagnosis, allow for geotagging an creating a network of data.
Vetted Performance Status
99% sensitivity and specificity to molecular results were claimed.
Safety
Unknown
Complementary Technical Systems
None
Academic Research and References
Dunning, L., Kroon, M., Hsiao, N., and Myer, L., 2017, Field Evaluation of HIV Point-of-Care Testing for Early Infant Diagnosis in Cape Town, South Africa, PloS One, 12(12), p. e0189226.
Vu, C., Chan, J., Todaro, M., Skafidas, S., and Kwan, P., 2015, Point-of-Care Molecular Diagnostic Devices: an Overview, Pharmacogenomics, 16(12), pp. 1399-1409.
Dorman, S., 2015, Advances in the Diagnosis of Tuberculosis: Current Status and Future Prospects, The International Journal of Tuberculosis and Lung Disease, 19(5), pp. 504-516.
Basha, I., Ho, E., 2017, Towards Multiplex Molecular Diagnosis—A Review of Microfluidic Genomics Technologies, Micromachines, 8(9), p. 266.
Compliance with regulations
QuantumDx plans to obtain CE marking for all of the Q-POC tests in the short term and then pursue a 510(k) submission with the US Food and Drug Administration.
Evaluation methods
Clinical trials planned in South Africa, sensitivity tests performed.
Other Information
None
Agriculture
December 27, 2023
Implemented by
Aquabox, UK
Agriculture
December 18, 2023
Implemented by
Be Girl
Agriculture
January 11, 2024
Implemented by
Kenya Ceramic Project (KCP)
Agriculture
January 8, 2024
Implemented by
DayOne Response
Agriculture
December 19, 2023
Implemented by
Hadleigh Health Technologies and Rice University
Agriculture
February 16, 2024
Implemented by
Eniware
Agriculture
December 19, 2023
Implemented by
GlobalNeoNat
Agriculture
November 17, 2023
Implemented by
AYZH
Agriculture
December 29, 2023
Implemented by
LifeStraw
Agriculture
December 16, 2024
Implemented by
MPOWERD
Agriculture
December 27, 2023
Implemented by
Aquabox, UK
Agriculture
December 18, 2023
Implemented by
Be Girl
Agriculture
January 11, 2024
Implemented by
Kenya Ceramic Project (KCP)
Agriculture
January 8, 2024
Implemented by
DayOne Response
Agriculture
December 19, 2023
Implemented by
Hadleigh Health Technologies and Rice University
Agriculture
February 16, 2024
Implemented by
Eniware
Agriculture
December 19, 2023
Implemented by
GlobalNeoNat
Agriculture
November 17, 2023
Implemented by
AYZH
Agriculture
December 29, 2023
Implemented by
LifeStraw
Agriculture
December 16, 2024
Implemented by
MPOWERD
Agriculture
December 27, 2023
Implemented by
Aquabox, UK
Agriculture
December 18, 2023
Implemented by
Be Girl
Agriculture
January 11, 2024
Implemented by
Kenya Ceramic Project (KCP)
Agriculture
January 8, 2024
Implemented by
DayOne Response
Agriculture
December 19, 2023
Implemented by
Hadleigh Health Technologies and Rice University
Agriculture
February 16, 2024
Implemented by
Eniware
Agriculture
December 19, 2023
Implemented by
GlobalNeoNat
Agriculture
November 17, 2023
Implemented by
AYZH
Agriculture
December 29, 2023
Implemented by
LifeStraw
Agriculture
December 16, 2024
Implemented by
MPOWERD
Have thoughts on how we can improve?
Give Us FeedbackNotifications